-- Invested more than $2.5 billion in research and development, an
increase of 11.1 percent from the previous year. Through medical
advancements and new scientific technologies, Abbott is tackling some
of today's most pressing chronic diseases -- diabetes, cancer and
-- Introduced the first and only co-formulated protease inhibitor tablet
suitable for children with HIV. The tablet does not require
refrigeration and does not need to be taken with food -- two important
advances in delivering HIV medicine. Kaletra (known as Aluvia in
developing countries) was filed or has been approved in 156 developed
and developing countries.
-- Supported science education in the United States through a new program
called "Labs Are Vital," which helps to raise awareness of the
life-saving work clinical laboratory professionals provide in improving
-- Launched pilot programs to enhance science education and worked closely
with teachers in several U.S. cities to promote science in the
classrooms. In 2008, Abbott aims to expand these programs across the
-- Became the first FORTUNE 500 company to go "carbon neutral" with its
fleet of sales vehicles.
-- Improved operations to help protect the environment, including reducing
carbon dioxide (CO2) emissions with plans to reduce total emissions by
30 percent by 2011.
-- Continued to work towards 2010 goals to reduce water usage, waste,
employee injuries and commercial vehicle fleet accidents to help
generate the greatest environmental, health and safety benefits.
About Abbott's 2007 Global Citizenship Report
Abbott's full 2007 report is no
Copyright©2008 PR Newswire.
All rights reserved